Controlled Vocabulary Gaps in Depression Biomarker Indexing: Implications for Psychedelic Trials

MeSH Indexing Fails to Capture Biomarker Sampling Site in Depression Studies

Recent meta-research published in October 2026 demonstrates that the Medical Subject Headings (MeSH) controlled vocabulary system, widely used for indexing biomedical literature, fails to consistently record whether depression biomarkers are measured in peripheral compartments (such as blood) or in the central nervous system (such as cerebrospinal fluid). This finding is based on an analysis of 1,166 PubMed records from January 2024 to June 2026, focusing on depression and biomarker research. Of these, only 825 were MEDLINE-indexed and thus eligible for MeSH analysis. The study found that 59.9% of indexed records lacked a marker-level descriptor, and 79.8% carried no site qualifier, meaning the sampling compartment was not recorded in the structured bibliographic record.

Mechanisms: Structural and Indexer Limitations in MeSH

The inability to capture sampling site information in MeSH arises from both indexer omissions and structural limitations of the controlled vocabulary itself. The 2026 MeSH descriptor file reveals that over half of all descriptors (56.2%) do not permit the '/blood' qualifier, and among marker-level descriptors, 12.3%—including C-reactive protein, the most frequently indexed marker—are barred from carrying this qualifier. Notably, the same descriptors may allow the '/cerebrospinal fluid' qualifier, creating an asymmetry in how peripheral and central measurements are indexed. The study further notes that primary research articles are more likely to record the sampling compartment than reviews (38.8% vs 14.8%), but the likelihood of recording is primarily determined by the number of descriptors eligible for site qualifiers, not study design. This structural blind spot means that even diligent indexers cannot always capture critical methodological details.

Policy and Research Implications for Psychedelic Trials

The inability of MeSH to reliably record biomarker sampling sites has significant implications for systematic reviews, meta-analyses, and regulatory submissions, especially in the context of psychedelic clinical trials. As biomarker endpoints—such as inflammatory markers—become increasingly important for stratifying patients and evaluating treatment response in difficult-to-treat depression, the inability to aggregate or audit data by sampling compartment introduces uncertainty into evidence synthesis. For example, peripheral biomarkers like blood-based C-reactive protein are imperfect proxies for central nervous system processes, a distinction that is critical when evaluating the mechanistic effects of psychedelic interventions. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) increasingly require precise methodological documentation for biomarker endpoints in Phase 2 and Phase 3 trials. The current indexing infrastructure may thus impede both regulatory review and the development of robust clinical guidelines.

Risks, Unknowns, and Real-World Consequences

The principal risk highlighted by this meta-research is that systematic reviews and meta-analyses may inadvertently aggregate studies measuring fundamentally different biological processes, leading to misleading conclusions about the efficacy or mechanism of psychedelic interventions for depression. This is particularly acute in the inflammatory endotype literature, where the distinction between central and peripheral markers is biologically meaningful. An additional, less obvious risk is that unindexed or misindexed studies—approximately one in five articles remain unindexed in closed years—are effectively invisible to evidence synthesis efforts reliant on MeSH. This creates a selection bias that may distort the perceived state of the science. Furthermore, the inability to audit or contest the compartmental distinction at the bibliographic level limits transparency and reproducibility in research synthesis, a failure mode not typically surfaced in discussions of psychedelic trial methodology.

Looking Forward: Infrastructure Needs and Interim Solutions

Addressing this blind spot will require coordinated action by indexing authorities, publishers, and the research community. One concrete step is for journals publishing psychedelic and depression biomarker studies to require explicit reporting of sampling compartment in abstracts and metadata, facilitating manual or automated extraction. Indexing authorities such as the U.S. National Library of Medicine could consider expanding site qualifiers or revising descriptor eligibility in future MeSH updates. For ongoing and planned psychedelic trials, sponsors and investigators should ensure that compartmental details are clearly documented in trial registries (e.g., ClinicalTrials.gov) and regulatory submissions. In the interim, systematic reviewers may need to supplement MeSH-based searches with full-text screening or machine learning approaches to capture critical methodological variables. As biomarker-driven stratification becomes central to the next generation of psychedelic trials, the research infrastructure must evolve to support accurate, reproducible synthesis and regulatory oversight.

By Dr. Alex Kim, PhD (Neuroscience, Meta-Research Specialist). Reviewed by Dr. Priya Shah, MD, MPH, on 2026-10-18. Research based on primary analysis of PubMed and MeSH descriptor files; see OpenAlex record for full study details.